Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-blind, randomized , placebo-controlled study to evaluate the safety and tolerability of AVT001, and to assess AVT001 as a potential treatment for type 1 diabetes (T1D). The trial will involve approximately 24 new-onset T1D subjects.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avotres Inc.

Criteria

Key Inclusion Criteria:

1. Diagnosis of type 1 diabetes, within 12 months of first dosing, confirmed by positive lab result for one or more of the following types of autoantibodies:

1. Glutamic acid decarboxylase (GAD65)

2. Insulinoma associated protein 2 (IA-2, also known as ICA-512)

3. Zinc transporter 8 (ZnT8).

2. Age 16 or older and able to provide informed consent/assent.

3. If a participant is female with reproductive potential, willing to avoid pregnancy through the duration of the trial.

4. Signed and dated written informed consent/assent.

Key Exclusion Criteria:

1. Poorly controlled diabetes despite insulin therapy, who in the opinion of the investigator would not be a good candidate for participation in a clinical trial

2. Screening hemoglobin <10.0 g/dL; leukocytes <3,000/uL; neutrophils <1,500/uL; lymphocytes <800/uL; platelets <100,000/uL

3. Screening Urine Albumin Excretion > 300mg/gmCr

4. Screening eGFR < 60 mL/min/1.73m2

5. Screening ALT or AST > 1.5x upper limit of normal (ULN)

6. Screening bilirubin > 2.0 mg / dL, or > 3.0 mg / dL for participants with Gilbert's Syndrome

7. Current use of immunosuppressive or immunomodulatory therapies, including pharmacologic doses of systemic steroids. However, topical steroidal creams and inhaled steroids without large systemic absorption are allowed.

8. Coincident medical condition likely to require immunosuppressive or immunomodulatory therapies.

9. Coincident medical condition likely to limit short term (5 year) life expectancy (malignancy, symptomatic coronary artery disease, recent stroke)

10. Prior radiation therapy, immunotherapy (within 1 year of screening), or chemotherapy

11. Serologic evidence of current HIV-1 or HIV-2 infection

12. Serologic evidence of hepatitis C infection

13. Serologic evidence of acute or chronic active hepatitis B as measured by Core Ab positive and / or Surface Antibody antigen positive

14. Subjects with other autoimmune conditions (except compensated or treated autoimmune thyroid, celiac, alopecia, or vitiligo diseases)

15. Women who are pregnant (pregnancy testing during screening), breastfeeding, or planning pregnancy during the study period

16. Inadequate venous access to support leukapheresis

17. Any condition that in the opinion of the investigator(s) would preclude the subject from participating in a clinical trial.

18. Abnormal screening ECG that in the opinion of the investigator or sponsor would pose a safety risk.